Melitracen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Melitracen is a thioxanthene neuroleptic indicated in the treatment of anxiety, depression, and asthenia.

Generic Name
Melitracen
DrugBank Accession Number
DB13384
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Structure
Thumb
Weight
Average: 291.438
Monoisotopic: 291.198699809
Chemical Formula
C21H25N
Synonyms
  • Melitracen
  • Melitraceno

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Melitracen.
AcarboseMelitracen may decrease the hypoglycemic activities of Acarbose.
AcebutololMelitracen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Aceclofenac.
AcemetacinThe risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Melitracen is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Melitracen.
AcetohexamideMelitracen may decrease the hypoglycemic activities of Acetohexamide.
AcetophenazineThe serum concentration of Melitracen can be increased when it is combined with Acetophenazine.
Acetylsalicylic acidThe risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Acetylsalicylic acid.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ANXISETMelitracen (10 MG) + Flupentixol (0.5 MG)Tablet, film coatedOralบริษัท ยูเนียนเมดดิคอล (ประเทศไทย) จำกัด2014-06-13Not applicableThailand flag
DEANXITMelitracen (10 MG) + Flupentixol (0.5 MG)Tablet, sugar coatedOralบริษัท บี.เอ็ล.ฮั้ว จำกัด1985-02-13Not applicableThailand flag
DEANXIT TABLETMelitracen (10 mg) + Flupentixol (0.5 mg)Tablet, film coatedOralLUNDBECK SINGAPORE PTE. LTD.1988-05-09Not applicable
DORMIR TABLET, 20 ADETMelitracen (10 mg) + Flupentixol (0.5 mg)TabletOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
ดิพรีซอลMelitracen (10 MG) + Flupentixol (0.5 MG)Tablet, film coatedOralบริษัท เภสัชกรรมศรีประสิทธิ์ จำกัด2018-02-09Not applicableThailand flag
ฟลูเทรสMelitracen (10 MG) + Flupentixol (0.5 MG)Tablet, film coatedOralบริษัท ยูนีซัน จำกัด2016-12-29Not applicableThailand flag

Categories

ATC Codes
N06CA02 — Melitracen and psycholepticsN06AA14 — Melitracen
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as anthracenes. These are organic compounds containing a system of three linearly fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Anthracenes
Sub Class
Not Available
Direct Parent
Anthracenes
Alternative Parents
Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Amine / Anthracene / Aromatic homopolycyclic compound / Hydrocarbon derivative / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound / Tertiary aliphatic amine / Tertiary amine
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Q7T0Y1109Z
CAS number
5118-29-6
InChI Key
GWWLWDURRGNSRS-UHFFFAOYSA-N
InChI
InChI=1S/C21H25N/c1-21(2)19-13-7-5-10-17(19)16(12-9-15-22(3)4)18-11-6-8-14-20(18)21/h5-8,10-14H,9,15H2,1-4H3
IUPAC Name
[3-(10,10-dimethyl-9,10-dihydroanthracen-9-ylidene)propyl]dimethylamine
SMILES
CN(C)CCC=C1C2=CC=CC=C2C(C)(C)C2=CC=CC=C12

References

General References
  1. FDA Thailand Product Information: Anxiset (melitracen/flupentixol) film-coated tablets [Link]
ChemSpider
23697
BindingDB
112783
RxNav
446248
ChEBI
135214
ChEMBL
CHEMBL110094
ZINC
ZINC000001482101
Wikipedia
Melitracen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentCompliance / Depression / Dyspepsia1
4CompletedTreatmentEmotional Disorders / Neurologic Disorders1
4CompletedTreatmentTinnitus1
3CompletedTreatmentGlobus1
1CompletedTreatmentHealthy Men and Women1
1CompletedTreatmentHealthy Subjects (HS)1
1, 2RecruitingTreatmentSyndrome X1
Not AvailableNot Yet RecruitingNot AvailableGastro-esophageal Reflux Disease (GERD)1
Not AvailableRecruitingNot AvailableSomatization Disorder1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, sugar coatedOral
Tablet, film coatedOral
Tablet, film coatedOral0.5 mg
Tablet
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00318 mg/mLALOGPS
logP5.4ALOGPS
logP4.95ChemAxon
logS-5ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity116.42 m3·mol-1ChemAxon
Polarizability36.16 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on June 23, 2017 20:41 / Updated on June 02, 2021 20:04